NovaCardia lands $48M in second round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
NovaCardia
|
$48M
|
Skyline Ventures and InterWest Partners |
NovaCardia which is developing drugs for cardiovascular disease. |
|
Athenagen
|
$50M
|
Sanderling Ventures and Clarus Ventures |
They will use much of the money to push the development of its candidates for neurovascular diseases. |
|
Amsterdam Molecular Therapeutics
|
$27.9M
|
ABN AMRO Capital/Life Sciences, Advent Venture Partners, Gilde Healthcare Partners and Crédit Agricole Private Equity |
The money will go to advancing AMT-011--AMT's lead product intended to treat lipoprotein lipase deficiency--from Phase II through to registration. |
|
Gamida Cell
|
$16M
|
Israel Healthcare Ventures |
The money will be used to expand Gamida Cell's tissue regeneration product pipeline (including a cardiac regeneration product). |